Johns Hopkins HIV Guide
Lenacapavir
INDICATIONS
FDA
FDA
- Lenacapavir is a HIV-1 capsid inhibitor, and is indicated for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection who are failing their current regimen due to resistance, intolerance, and/or safety considerations as part of combination therapy wtih other antivirals.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: September 3, 2023
Citation
Dzintars, Kathryn. "Lenacapavir." Johns Hopkins HIV Guide, 2023. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545318/all/Lenacapavir.
Dzintars K. Lenacapavir. Johns Hopkins HIV Guide. 2023. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545318/all/Lenacapavir. Accessed September 29, 2023.
Dzintars, K. (2023). Lenacapavir. In Johns Hopkins HIV Guide https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545318/all/Lenacapavir
Dzintars K. Lenacapavir [Internet]. In: Johns Hopkins HIV Guide. ; 2023. [cited 2023 September 29]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545318/all/Lenacapavir.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Lenacapavir
ID - 545318
A1 - Dzintars,Kathryn,Pharm.D., BCPS
Y1 - 2023/09/03/
BT - Johns Hopkins HIV Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545318/all/Lenacapavir
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -
